| PD-1/PD-L1治疗非小细胞肺癌的研究进展 |
| |
| 引用本文： | 阎卫亮,王华庆.PD-1/PD-L1治疗非小细胞肺癌的研究进展[J].中国肿瘤临床,2018,45(13):699-703. |
| |
| 作者姓名： | 阎卫亮 王华庆 |
| |
| 作者单位： | ①.天津医科大学第二医院胸外科（天津市300211） |
| |
| 摘 要： | 程序性死亡受体-1（programmed cell death-1，PD-1）/程序性死亡配体-1（programmed cell death-ligand 1，PD-L1）信号通路与肿瘤免疫逃逸密切相关，针对PD-1/PD-L1通路的免疫检查点抑制剂为非小细胞肺癌（non-small cell lung cancer，NSCLC）患者提供了一种新的治疗选择，并且显示出良好的疗效和安全性。本文对PD-1/PD-L1抑制剂治疗NSCLC的临床研究进展进行综述。
|
| 关 键 词： | 免疫治疗 程序性死亡受体-1 程序性死亡配体-1 非小细胞肺癌 |
| 收稿时间： | 2018-04-16 |
Research progress of PD-1/PD-L1 in the treatment of non-small cell lung cancer |
| |
| Affiliation: | ①.Department of Thoracic Surgery, The Second Hospital of Tianjin Medical University, Tianjin 200211, China②.Tianjin People's Hospital, 300000, China |
| |
| Abstract: | The programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) signaling pathway is closely related to the immune escape mechanism. Immune checkpoint inhibitors targeting PD-1/PD-L1 have become an important alternative for treating advanced non-small cell lung cancer (NSCLC) patients; NSCLC patients have shown considerable responses and good tolerance to these agents. The article reviews the current clinical researches on PD-1/PD-L1 for NSCLC treatment. |
| |
| Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载全文 |
